In the Phase III SERENA-6 trial, camizestrant—in combination with CDK-inhibitors—beat out current standard-of-care treatments ...

As high prices and supply issues drive consumers to alternative markets for GLP-1s, physicians aren’t too interested in using ...

SpringWorks Therapeutics sprung out of Pfizer’s storeroom, when a rare disease advocacy group pushed to keep a program for ...

While many industry players and observers have high hopes for the EPIC Act, some say budgetary headwinds could make it ...

Kiniksa will now focus its development efforts on the IL-1 blocker KPL-387, which it is testing for recurrent pericarditis ...

In the Phase III trial, 41.9% of pediatric Tourette syndrome patients relapsed after ecopipam treatment, as compared with ...

As FDA seeks to rehire some fired employees, Donald Trump threatens to enact tariffs on pharma companies unless they reshore manufacturing; another lawsuit hits the complex GLP-1 compounding space as ...

The Outsourcing Facilities Association, a trade group representing compounders, filed a similar lawsuit in October last year ...

The latest Repare Therapeutics layoffs will include its chief medical officer and could leave the biotech with fewer than 35 ...

Deerfield Management claims that Alcon Research is seeking a discounted takeover of Aurion Biotech while blocking the startup ...

BridGene strikes another partnership with Takeda as the latter company continues its dealmaking streak, following high-ticket ...

The World Health Organization names antimicrobial resistance as one of the most urgent public health threats, but it remains ...